If you're specifying pharma packaging for the first time — or reviewing an existing supply chain — you'll encounter these two terms constantly: pilfer proof caps and tamper evident closures. Procurement teams, regulatory affairs professionals, and pharmacists use them interchangeably, but they have distinct technical meanings. Choosing the wrong type can create a compliance gap or a product recall risk.
What Is a Tamper Evident Cap?
A tamper evident closure provides visible evidence that a container has been opened. The key word is "evidence" — the design makes it impossible to open the container without leaving a clear, visible sign. Once the seal is broken, it cannot be concealed.
Common tamper evident designs include:
- Break-bands: A thin band attached to the bottom of the cap that tears away on first opening.
- Induction seals: A foil membrane heat-bonded to the bottle neck under the cap — the cap can be removed and replaced, but the broken foil shows the bottle was opened.
- Shrink bands: A heat-shrunk film over the cap-bottle junction that tears on opening.
Tamper evidence is a regulatory requirement under most pharmacopoeias — including IP (Indian Pharmacopoeia), USP, and EP — for OTC and prescription liquid medicines.
What Is a Pilfer Proof Cap?
A pilfer proof cap goes one step further. Where tamper evident shows evidence of opening, a pilfer proof cap prevents the container from being resealed after the first opening. The closure mechanism is physically destroyed by the first opening — there is no way to reattach it without visible damage.
In pharmaceutical packaging, "pilfer proof" specifically addresses the risk of product adulteration: someone cannot refill a bottle with a counterfeit substance and reseal it convincingly. This is particularly relevant for:
- High-value liquid formulations
- Products with street-drug abuse potential
- Export products entering markets with known counterfeiting risk
How the Two Overlap in Practice
Most modern pharmaceutical caps are both tamper evident and pilfer proof — the distinction matters more for specification documents and regulatory dossiers than for day-to-day procurement. The most common product in this category is the CRC-PP (Child Resistant Pilfer Proof) cap, which adds child resistance on top of both tamper evidence and pilferage prevention.
Which One Does Your Regulatory Submission Need?
For Indian market submissions (CDSCO), the Drugs and Cosmetics Act Schedule M requires tamper evidence for primary packaging of liquid oral dosage forms. The Schedule does not explicitly distinguish pilfer proof as a separate requirement, but most regulatory reviewers expect a pilfer proof construction for Schedule H and Schedule H1 medicines.
For US FDA submissions (NDA/ANDA), 21 CFR Part 211.132 requires tamper evident packaging for OTC human drug products. The FDA guidance document on tamper evident packaging provides detailed design requirements.
Right Angle Pharmapack's Range
We manufacture pilfer proof caps and child resistant CRC-PP closures for the most common pharma bottle neck sizes: 18mm, 24mm, 28mm, 33mm, and 38mm. All products are tested to ISO 8317 (child resistance) and certified under ISO 15378 and WHO-GMP.
If you're unsure which closure type your product specification requires, contact our technical sales team — we review formulation type, bottle geometry, regulatory market, and patient demographic to recommend the right solution.